Expression of DNA repair proteins in endometrial cancer predicts disease outcome

Paulette Mhawech-Fauceglia, Dan Wang, Grace Kim, Maryam Sharifian, Xiwie Chen, Qian Liu, Yvonne G. Lin, Song Liu, Tanja Pejovic

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective The consequences of defective homologous recombination and other DNA repair pathways are important in disease outcomes of numerous tumor types. The objective of this study was to explore BRCA1, PARP, FANCD2, PTEN, H2AX, and ATM protein expression in endometrial cancer (EC). Methods PARP1, γH2AX, ATM, FANCD2, PTEN, BRCA1, and p53 proteins were evaluated in EC tissue microarray (TMA) and their expressions were correlated with clinical and pathological parameters in 357 patients. Results In type I EC, PARP1 +, ATM+, and FANCD2+ were associated with high tumor grade (p 0.031, p 0.0045, p 0.0062 respectively); γH2AX+ and FANCD2+ with advanced tumor stage (p 0.0004, p 0.0085 respectively); γH2AX+, FANCD2+ and p53+ with the presence of lympho-vascular invasion (p 0.0004, p 0.0042, p 0.0098 respectively); and γH2AX+ and ATM+ with tumor recurrence (p 0.0203, p 0.0465) respectively. In type II EC, only PARP1 + was associated with tumor stage (p 0.0499). EC patients with p53+ or FANCD2+ were more likely to recur with 5 year recurrence free survival (RFS) probability of 71.4% in comparison to 85.5% for the other patients and they were more likely to have shorter 5 year overall survival (OS) of 66.46% in comparison to 78.5% of those other patients Finally, patients with ATM+ and p53+ or FANCD2+ were more likely to recur with 5 year RFS probability of 68% versus 80.3% for the other patients. Conclusion DNA repair proteins seemed to play an important role in EC, and their expressions can forecast for poor outcomes.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalGynecologic Oncology
Volume132
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Endometrial Neoplasms
DNA Repair
Proteins
Neoplasms
Recurrence
Survival
Ataxia Telangiectasia Mutated Proteins
BRCA1 Protein
PTEN Phosphohydrolase
Recombinational DNA Repair
Blood Vessels

Keywords

  • DNA repair proteins
  • Endometrial cancer
  • Immunohistochemistry
  • Patient outcome

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Expression of DNA repair proteins in endometrial cancer predicts disease outcome. / Mhawech-Fauceglia, Paulette; Wang, Dan; Kim, Grace; Sharifian, Maryam; Chen, Xiwie; Liu, Qian; Lin, Yvonne G.; Liu, Song; Pejovic, Tanja.

In: Gynecologic Oncology, Vol. 132, No. 3, 2014, p. 593-598.

Research output: Contribution to journalArticle

Mhawech-Fauceglia, P, Wang, D, Kim, G, Sharifian, M, Chen, X, Liu, Q, Lin, YG, Liu, S & Pejovic, T 2014, 'Expression of DNA repair proteins in endometrial cancer predicts disease outcome', Gynecologic Oncology, vol. 132, no. 3, pp. 593-598. https://doi.org/10.1016/j.ygyno.2014.02.002
Mhawech-Fauceglia, Paulette ; Wang, Dan ; Kim, Grace ; Sharifian, Maryam ; Chen, Xiwie ; Liu, Qian ; Lin, Yvonne G. ; Liu, Song ; Pejovic, Tanja. / Expression of DNA repair proteins in endometrial cancer predicts disease outcome. In: Gynecologic Oncology. 2014 ; Vol. 132, No. 3. pp. 593-598.
@article{26bb561b19c64c0f8c5386135fbe5a4c,
title = "Expression of DNA repair proteins in endometrial cancer predicts disease outcome",
abstract = "Objective The consequences of defective homologous recombination and other DNA repair pathways are important in disease outcomes of numerous tumor types. The objective of this study was to explore BRCA1, PARP, FANCD2, PTEN, H2AX, and ATM protein expression in endometrial cancer (EC). Methods PARP1, γH2AX, ATM, FANCD2, PTEN, BRCA1, and p53 proteins were evaluated in EC tissue microarray (TMA) and their expressions were correlated with clinical and pathological parameters in 357 patients. Results In type I EC, PARP1 +, ATM+, and FANCD2+ were associated with high tumor grade (p 0.031, p 0.0045, p 0.0062 respectively); γH2AX+ and FANCD2+ with advanced tumor stage (p 0.0004, p 0.0085 respectively); γH2AX+, FANCD2+ and p53+ with the presence of lympho-vascular invasion (p 0.0004, p 0.0042, p 0.0098 respectively); and γH2AX+ and ATM+ with tumor recurrence (p 0.0203, p 0.0465) respectively. In type II EC, only PARP1 + was associated with tumor stage (p 0.0499). EC patients with p53+ or FANCD2+ were more likely to recur with 5 year recurrence free survival (RFS) probability of 71.4{\%} in comparison to 85.5{\%} for the other patients and they were more likely to have shorter 5 year overall survival (OS) of 66.46{\%} in comparison to 78.5{\%} of those other patients Finally, patients with ATM+ and p53+ or FANCD2+ were more likely to recur with 5 year RFS probability of 68{\%} versus 80.3{\%} for the other patients. Conclusion DNA repair proteins seemed to play an important role in EC, and their expressions can forecast for poor outcomes.",
keywords = "DNA repair proteins, Endometrial cancer, Immunohistochemistry, Patient outcome",
author = "Paulette Mhawech-Fauceglia and Dan Wang and Grace Kim and Maryam Sharifian and Xiwie Chen and Qian Liu and Lin, {Yvonne G.} and Song Liu and Tanja Pejovic",
year = "2014",
doi = "10.1016/j.ygyno.2014.02.002",
language = "English (US)",
volume = "132",
pages = "593--598",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of DNA repair proteins in endometrial cancer predicts disease outcome

AU - Mhawech-Fauceglia, Paulette

AU - Wang, Dan

AU - Kim, Grace

AU - Sharifian, Maryam

AU - Chen, Xiwie

AU - Liu, Qian

AU - Lin, Yvonne G.

AU - Liu, Song

AU - Pejovic, Tanja

PY - 2014

Y1 - 2014

N2 - Objective The consequences of defective homologous recombination and other DNA repair pathways are important in disease outcomes of numerous tumor types. The objective of this study was to explore BRCA1, PARP, FANCD2, PTEN, H2AX, and ATM protein expression in endometrial cancer (EC). Methods PARP1, γH2AX, ATM, FANCD2, PTEN, BRCA1, and p53 proteins were evaluated in EC tissue microarray (TMA) and their expressions were correlated with clinical and pathological parameters in 357 patients. Results In type I EC, PARP1 +, ATM+, and FANCD2+ were associated with high tumor grade (p 0.031, p 0.0045, p 0.0062 respectively); γH2AX+ and FANCD2+ with advanced tumor stage (p 0.0004, p 0.0085 respectively); γH2AX+, FANCD2+ and p53+ with the presence of lympho-vascular invasion (p 0.0004, p 0.0042, p 0.0098 respectively); and γH2AX+ and ATM+ with tumor recurrence (p 0.0203, p 0.0465) respectively. In type II EC, only PARP1 + was associated with tumor stage (p 0.0499). EC patients with p53+ or FANCD2+ were more likely to recur with 5 year recurrence free survival (RFS) probability of 71.4% in comparison to 85.5% for the other patients and they were more likely to have shorter 5 year overall survival (OS) of 66.46% in comparison to 78.5% of those other patients Finally, patients with ATM+ and p53+ or FANCD2+ were more likely to recur with 5 year RFS probability of 68% versus 80.3% for the other patients. Conclusion DNA repair proteins seemed to play an important role in EC, and their expressions can forecast for poor outcomes.

AB - Objective The consequences of defective homologous recombination and other DNA repair pathways are important in disease outcomes of numerous tumor types. The objective of this study was to explore BRCA1, PARP, FANCD2, PTEN, H2AX, and ATM protein expression in endometrial cancer (EC). Methods PARP1, γH2AX, ATM, FANCD2, PTEN, BRCA1, and p53 proteins were evaluated in EC tissue microarray (TMA) and their expressions were correlated with clinical and pathological parameters in 357 patients. Results In type I EC, PARP1 +, ATM+, and FANCD2+ were associated with high tumor grade (p 0.031, p 0.0045, p 0.0062 respectively); γH2AX+ and FANCD2+ with advanced tumor stage (p 0.0004, p 0.0085 respectively); γH2AX+, FANCD2+ and p53+ with the presence of lympho-vascular invasion (p 0.0004, p 0.0042, p 0.0098 respectively); and γH2AX+ and ATM+ with tumor recurrence (p 0.0203, p 0.0465) respectively. In type II EC, only PARP1 + was associated with tumor stage (p 0.0499). EC patients with p53+ or FANCD2+ were more likely to recur with 5 year recurrence free survival (RFS) probability of 71.4% in comparison to 85.5% for the other patients and they were more likely to have shorter 5 year overall survival (OS) of 66.46% in comparison to 78.5% of those other patients Finally, patients with ATM+ and p53+ or FANCD2+ were more likely to recur with 5 year RFS probability of 68% versus 80.3% for the other patients. Conclusion DNA repair proteins seemed to play an important role in EC, and their expressions can forecast for poor outcomes.

KW - DNA repair proteins

KW - Endometrial cancer

KW - Immunohistochemistry

KW - Patient outcome

UR - http://www.scopus.com/inward/record.url?scp=84896389575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896389575&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.02.002

DO - 10.1016/j.ygyno.2014.02.002

M3 - Article

C2 - 24508840

AN - SCOPUS:84896389575

VL - 132

SP - 593

EP - 598

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -